Get the Stockscreener App
2.605
1.70%
-0.045
Immunitybio Inc stock is traded at $2.605, with a volume of 1.15M.
It is down -1.70% in the last 24 hours and down -3.52% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.65
Open:
$2.65
24h Volume:
1.15M
Relative Volume:
0.13
Market Cap:
$2.29B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.6856
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-3.87%
1M Performance:
-3.52%
6M Performance:
-17.56%
1Y Performance:
-52.03%
1-Day Range:
$2.60
$2.6729
1-Week Range:
$2.60
$3.11
52-Week Range:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.60 | 2.52B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.51 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.00 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
592.94 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
300.80 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Natural Killer Cell Therapies Clinical Trials, Companies, - openPR.com
How does ImmunityBio Inc. compare to its industry peersDiscover breakthrough investment opportunities - jammulinksnews.com
What is ImmunityBio Inc. company’s growth strategyMaximize your portfolio’s growth with expert tips - jammulinksnews.com
Is ImmunityBio Inc. a growth stock or a value stockCapitalize on emerging market opportunities - jammulinksnews.com
When is ImmunityBio Inc. stock expected to show significant growthInvest confidently with professional market insights - jammulinksnews.com
What institutional investors are buying ImmunityBio Inc. stockAchieve breakthrough performance in the market - jammulinksnews.com
Published on: 2025-07-28 00:26:40 - jammulinksnews.com
How ImmunityBio Inc. stock reacts to Fed policy changesShort Term Profit Focus - metal.it
ImmunityBio’s Stock Soars: Buy or Sell? - timothysykes.com
ImmunityBio (IBRX) Secures $80M Through Direct Offering | IBRX S - GuruFocus
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - BioSpace
ImmunityBio announces $80M registered direct offering - TipRanks
What analysts say about ImmunityBio Inc. stockHigh-yield investments - PrintWeekIndia
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Lelezard
ImmunityBio Announces $80 Million Securities Purchase - TipRanks
ImmunityBio's Q2 Preliminary Revenue: A Strategic Inflection Point in the Biotech Immune Therapeutics Sector - AInvest
ImmunityBio (IBRX) Achieves Significant Revenue Growth in Q2 2025 | IBRX Stock News - GuruFocus
ImmunityBio's Q2 Earnings and Revenue Growth: Assessing the Path to Sustainable Value Creation - AInvest
Is ImmunityBio Inc. a good long term investmentMarket-leading profit generation - Autocar Professional
ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN
What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga
ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha
ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com
ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN
ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks
ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks
ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener
ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):